Drug Profile
Apomorphine sublingual film - Sumitomo Pharma America
Alternative Names: APL-130277; Apomorphine HCI; Apomorphine HCI sublingual film; Apomorphine Hydrochloride Sublingual Thin Film; KYNMOBILatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Adagio Pharmaceuticals
- Developer Sumitomo Pharma America
- Class Analgesics; Antiparkinsonians; Aporphines; Erectile dysfunction therapies; Quinolines; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists; Heat shock transcription factor stimulants; NF E2 related factor 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Parkinson's disease
Most Recent Events
- 08 Nov 2022 Sunovion completes phase III CTH301 trial in Parkinson's disease in USA, Austria, Canada, France,Germany, Italy, Spain and United Kingdom (Sublingual) (NCT02542696) (EudraCT2016-000637-43)
- 12 Sep 2021 Interim efficacy and adverse events data from a phase III CTH-301 trial in Parkinson's disease released by Sunovion Pharmaceuticals
- 02 Sep 2021 Sunovion Pharmaceuticals licenses apomorphine sublingual film to BIAL in Europe